Thermo Fisher Scientific
The growth of bio-therapeutics has occurred mainly due to the greater success rates within the clinical trials phase of drug development. This means that more drugs are being brought to market. Due to their complex nature, bio-therapeutics have a propensity to change structure which can have a detrimental effect on the efficacy of the drug. As a consequence, peptide mapping is mandated at all stages of the drug development pipeline to ensure integrity. The sample preparation stage of this process is complex, laborious, subject to error anddifficult to automate. This webcast details how new technologies can deliver peptide mapping which is:
Key Learning Objectives
Dr. Ken Cook, EU Bio-Separations Expert, Thermo Fisher Scientific
Dr. Sara Carillo, Applications Development Team Leader, The National Institute for Bioprocessing Research and Training (NIBRT)
* Required field
Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.